BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency

• Targeted RNAi screen identifies host proteins that impede early-stage HIV-1 replication
• BIRC2/cIAP1 is a negative regulator of LTR-dependent HIV-1 transcription
• BIRC2 depletion by Smac mimetic activates NF-κB signaling and reverses HIV-1 latency
• Smac mimetic and HDAC inhibitor synergize to reverse HIV-1 latency in vitro and ex vivo

SummaryCombination antiretroviral therapy (ART) is able to suppress HIV-1 replication to undetectable levels. However, the persistence of latent viral reservoirs allows for a rebound of viral load upon cessation of therapy. Thus, therapeutic strategies to eradicate the viral latent reservoir are critically needed. Employing a targeted RNAi screen, we identified the ubiquitin ligase BIRC2 (cIAP1), a repressor of the noncanonical NF-κB pathway, as a potent negative regulator of LTR-dependent HIV-1 transcription. Depletion of BIRC2 through treatment with small molecule antagonists known as Smac mimetics enhanced HIV-1 transcription, leading to a reversal of latency in a JLat latency model system. Critically, treatment of resting CD4+ T cells isolated from ART-suppressed patients with the histone deacetylase inhibitor (HDACi) panobinostat together with Smac mimetics resulted in synergistic activation of the latent reservoir. These data implicate Smac mimetics as useful agents for shock-and-kill strategies to eliminate the latent HIV reservoir.

Graphical AbstractFigure optionsDownload high-quality image (146 K)Download as PowerPoint slide